22407_Addressing Challenges:Best Practices for DOAC Reversal in Intracranial Hemorrhage

In this symposium, an expert multidisciplinary faculty will provide insights into and interpretations of clinical data, and challenging cases will reinforce key elements of prudent management of major bleeding in patients taking DOACs and experiencing intracranial hemorrhage.

Direct oral anticoagulants (DOACs) have become widely used for the prevention and treatment of venous thromboembolism, stroke prevention in atrial fibrillation, and management of patients with coronary artery disease or peripheral artery
disease. Large clinical trials have demonstrated that DOACs are as effective and safer than warfarin; DOACs are now widely
recommended by guidelines. Despite their superior safety, a small percentage of patients suffer intracranial hemorrhage, a devastating injury with high morbidity and mortality. Specific agents that reverse anticoagulation with factor Xa inhibition
and with oral direct thrombin inhibition have demonstrated effectiveness in clinical trials and are now preferred therapies in guidelines and statements from the American Heart Association/ American Stroke Association (endorsed by multiple societies
including the Neurocritical Care Society) and the American College of Cardiology Expert Consensus Decision Pathway. In this symposium, an expert multidisciplinary faculty will provide insights into and interpretations of clinical data, and challenging
cases will reinforce key elements of prudent management of major bleeding in patients taking DOACs and experiencing intracranial hemorrhage.

Login to your Account